ANDA 208607, held by ANI Pharmaceuticals. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 208607 (Methylphenidate Hydrochloride), held by ANI Pharmaceuticals, was first approved by FDA on Jul 14, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 14, 2017 | Original application | Approved |
| Methylphenidate Hydrochloride18MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride27MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride36MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride54MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters